Merck Sharp & Dohme Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1891-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.msd.com
Clinical Trials
152
Active:149
Completed:1
Trial Phases
1 Phases
Phase 1:99
Drug Approvals
14
PHILIPPINES:7
FDA:5
NMPA:2
Drug Approvals
Imipenem and Cilastatin Sodium for Injection
- Product Name
- 泰能
- Approval Number
- 国药准字J20180060
- Approval Date
- Apr 17, 2018
NMPA
Raltegravir Potassium for oral suspension
- Product Name
- 艾生特
- Approval Number
- H20180006
- Approval Date
- Apr 12, 2018
NMPA
Clinical Trials
Distribution across different clinical trial phases (99 trials with phase data)• Click on a phase to view related trials
Phase 1
99 (100.0%)No trials found
News
Supreme Court's Merck v. Albrecht Decision Continues to Reshape Drug Litigation
The Supreme Court's decision in _Merck Sharp & Dohme Corp. v. Albrecht_ has significantly impacted preemption defenses in pharmaceutical litigation, particularly concerning failure-to-warn claims.